,ACSS2

Liliana H Mochmann1,2, Denise Treue3, Michael Bockmayr3,4

  • 1Institute of Pathology, Ludwig-Maximilians-Universität München, Munich, Germany.

Cancer gene therapy
|June 8, 2024
PubMed
概括

介质细胞层保护急性髓性白血病 (AML) 细胞免受治疗. 向乙-CoA合成酶2 (ACSS2) 与基因素脱乙酶抑制剂 (HDACi) 减少AML的生长和耐药性,确定预后不佳的AML亚型.